Combined Chemo-Anti-Inflammatory Prodrugs and Nanoparticles

Rakesh K. Pathak; Shanta Dhar

doi:10.1055/s-0035-1561440

Synlett, Table of Contents

Synlett 2016; 27(11): 1607-1612
DOI: 10.1055/s-0035-1561440

synpacts

Combined Chemo-Anti-Inflammatory Prodrugs and Nanoparticles

Rakesh K. Pathak

NanoTherapeutics Research Laboratory, Department of Chemistry, University of Georgia, Athens, GA 30602, USA Email: shanta@uga.edu

,

Shanta Dhar*

NanoTherapeutics Research Laboratory, Department of Chemistry, University of Georgia, Athens, GA 30602, USA Email: shanta@uga.edu

› Author Affiliations

Abstract

All articles of this category

Abstract

Combining multiple drugs in one platform has the ability to override the limitations of singly administered therapeutic and may provide potential alternative treatment options for aggressive prostate cancer resistant to conventional chemotherapy. For in vivo applications, combination therapeutics should be engineered to include nanoparticles for efficacious delivery. Here, we discuss the aspects of combining chemotherapy with anti-inflammatory drugs for metastatic castration resistant prostate cancer. We highlight the concept of combining cisplatin and Aspirin in a single platinum(IV) prodrug for efficacious in vitro biological actions. These two drugs were further incorporated in an engineered biodegradable polymer, which can self-assemble in the presence of a block copolymer to controlled-release nanoparticles to deliver multiple therapeutics in a predefined ratio.

1 Introduction

2 Chemo-Anti-inflammatory Approaches for Chemo-Resistant Prostate Cancer: Challenges and Opportunities

3 Chemo-Anti-inflammatory Platinum(IV) Prodrugs

4 Polymeric Nanoparticle for Co-delivery of Cisplatin and Aspirin

5 Future Perspectives

Key words

combination therapy - Platin-A - cisplatin - Aspirin - polymeric nanoparticles - inflammation - cancer

Full Text

References

References
1 Sfanos KS, De Marzo AM. Histopathology 2012; 60: 199
2 Quail DF, Joyce JA. Nat. Med. 2013; 19: 1423
3 de Groot DJ. A, de Vries EG. E, Groen HJ. M, de Jong S. Crit. Rev. Oncol. Hemat. 2007; 61: 52
4 Dong H, Liu G, Jiang B, Guo J, Tao G, Yiu WE. I, Zhou J, Li G. Biomed. Rep. 2014; 2: 344
5 Rautio J, Kumpulainen H, Heimbach T, Oliyai R, Oh D, Jarvinen T, Savolainen J. Nat. Rev. Drug Discovery 2008; 7: 255
6 Singh Y, Palombo M, Sinko PJ. Curr. Med. Chem. 2008; 15: 1802
7 Jia J, Zhu F, Ma X, Cao ZW, Li YX, Chen YZ. Nat. Rev. Drug Discovery 2009; 8: 111
8 Huttunen KM, Raunio H, Rautio J. Pharmacol. Rev. 2011; 63: 750
9 Yang Y.-H, Aloysius H, Inoyama D, Chen Y, Hu L.-Q. Acta. Pharm. Sin. B 2011; 1: 143
10 Rosenberg B, Van Camp L, Krigas T. Nature (London, U.K.) 1965; 205: 698
11 Dasari S, Tchounwou PB. Eur. J. Pharmacol. 2014; 740: 364
12 Rosenberg B, VanCamp L. Cancer Res. 1970; 30: 1799
13 Zorbas-Seifried S, Jakupec MA, Kukushkin NV, Groessl M, Hartinger CG, Semenova O, Zorbas H, Kukushkin VY, Keppler BK. Mol. Pharmacol. 2007; 71: 357
14 White JD, Haley MM, DeRose VJ. Acc. Chem. Res. 2016; 49: 56
15 Wilson JJ, Lippard SJ. Chem. Rev. 2014; 114: 4470
16 Shi Y, Liu S.-A, Kerwood DJ, Goodisman J, Dabrowiak JC. J. Inorg. Biochem. 2012; 107: 6
17 Wexselblatt E, Gibson D. J. Inorg. Biochem. 2012; 117: 220
18 Hall MD, Mellor HR, Callaghan R, Hambley TW. J. Med. Chem. 2007; 50: 3403
19 Rayburn ER, Ezell SJ, Zhang R. Mol. Cell Pharmacol. 2009; 1: 29
20 Ricciotti E, FitzGerald GA. Arterioscler., Thromb., Vasc. Biol. 2011; 31: 986
21 Greenhough A, Smartt HJ. M, Moore AE, Roberts HR, Williams AC, Paraskeva C, Kaidi A. Carcinogenesis 2009; 30: 377
22 Alfonso L, Ai G, Spitale RC, Bhat GJ. Br. J. Cancer 2014; 111: 61
23 Rybak LP, Ramkumar V. Kidney Int. 2007; 72: 931
24 Choudhury D, Ahmed Z. Nat. Clin. Pract. Neph. 2006; 2: 80
25 Pathak RK, Marrache S, Choi JH, Berding TB, Dhar S. Angew. Chem. Int. Ed. 2014; 53: 1963
26 Pathak RK, Dhar S. J. Am. Chem. Soc. 2015; 137: 8324
27 Siegel RL, Miller KD, Jemal A. CA Cancer J. Clin. 2015; 65: 5
28 Pavuk M, Michalek JE, Ketchum NS. J. Expos. Sci. Environ. Epidemiol. 2005; 16: 184
29 Zullig LL, Jackson GL, Dorn RA, Provenzale DT, McNeil R, Thomas CM, Kelley MJ. Mil. Med. 2012; 177: 693
30 Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Nat. Clin. Pract. Urol. 2009; 6: 76
31 Datta K, Muders M, Zhang H, Tindall DJ. Future Oncol. 2010; 6: 823
32 Merseburger AS, Haas GP, von Klot C.-A. Ther. Adv. Urol. 2015; 7: 9
33 Abidi A. J. Pharmacol. Pharmacother. 2013; 4: 230
34 Mitragotri S, Burke PA, Langer R. Nat. Rev. Drug Discov. 2014; 13: 655
35 Cheng Q, Shi H, Wang H, Min Y, Wang J, Liu Y. Chem. Commun. 2014; 50: 7427
36 Cheng Q, Shi H, Huang H, Cao Z, Wang J, Liu Y. Chem. Commun. 2015; 51: 17536
37 Neumann W, Crews BC, Sárosi MB, Daniel CM, Ghebreselasie K, Scholz MS, Marnett LJ, Hey-Hawkins E. ChemMedChem 2015; 10: 183
38 Johnstone TC, Lippard SJ. Inorg. Chem. 2013; 52: 9915
39 Sinisi M, Intini FP, Natile G. Inorg. Chem. 2012; 51: 9694
40 Wexselblatt E, Yavin E, Gibson D. Angew. Chem. Int. Ed. 2013; 52: 6059
41 Marrache S, Pathak RK, Dhar S. Proc. Natl. Acad. Sci. U.S.A. 2014; 111: 10444
42 Kalathil AA, Kumar A, Banik B, Ruiter TA, Pathak RK, Dhar S. Chem. Commun. 2016; 52: 140
43 Feldhaeusser B, Platt SR, Marrache S, Kolishetti N, Pathak RK, Montgomery DJ, Reno LR, Howerth E, Dhar S. Nanoscale 2015; 7: 13822